News from the FDA/CDC
News from the FDA/CDC
Zika’s 2017 summer less active than 2016
Warmer weather did not bring about an increase in activity.
News from the FDA/CDC
Young adults lead the ranks of recently insured
Since 2010, Americans aged 18-29 years have seen a larger drop in their uninsured rate than those younger and older.
News from the FDA/CDC
Safety issues not that unusual in medical offices
Pharmacies may correct or clarify prescriptions, and lab results aren’t ready when needed.
News from the FDA/CDC
Less than half of office visits involve primary care
Patients aged 45 years and over are more likely to see a specialist.
News from the FDA/CDC
First IL-23 blocker, guselkumab, earns FDA approval for psoriasis
The approved indication is for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
News from the FDA/CDC
FDA asks drug maker to shelve Opana ER
This marks the first time the agency has acted to remove an opioid pain medication because of the public health consequences of abuse.
News from the FDA/CDC
Zika-related birth defects up in recent weeks
Almost 20% of all 2016-2017 live births with Zika-related birth defects were reported in the last month.
News
FDA approves first specific treatment for giant cell arteritis
The approval of tocilizumab was made with breakthrough therapy and priority review designations.
News from the FDA/CDC
Canagliflozin gets boxed warning for amputation
The risk of lower limb amputation associated with canagliflozin is now great enough to receive a boxed warning.
News from the FDA/CDC
Genital HPV prevalence tops 42% in adults
Men aged 18-59 years were significantly more likely than women to have any genital HPV and high-risk genital HPV.
News from the FDA/CDC
Dupilumab approval marks the first targeted treatment for AD
The first targeted biologic therapy approved for treating atopic dermatitis provides a welcome, long-awaited alternative to currently available...